|
1
|
Gurard-Levin ZA, Quivy JP and Almouzni G:
Histone chaperones: Assisting histone traffic and nucleosome
dynamics. Annu Rev Biochem. 83:487–517. 2014.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Daganzo SM, Erzberger JP, Lam WM,
Skordalakes E, Zhang R, Franco AA, Brill SJ, Adams PD, Berger JM
and Kaufman PD: Structure and function of the conserved core of
histone deposition protein Asf1. Curr Biol. 13:2148–2158.
2003.PubMed/NCBI View Article : Google Scholar
|
|
3
|
English CM, Adkins MW, Carson JJ,
Churchill ME and Tyler JK: Structural basis for the histone
chaperone activity of Asf1. Cell. 127:495–508. 2006.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Natsume R, Eitoku M, Akai Y, Sano N,
Horikoshi M and Senda T: Structure and function of the histone
chaperone CIA/ASF1 complexed with histones H3 and H4. Nature.
46:338–341. 2007.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Tagami H, Ray-Gallet D, Almouzni G and
Nakatani Y: Histone H3.1 and H3.3 complexes mediate nucleosome
assembly pathways dependent or independent of DNA synthesis. Cell.
116:51–61. 2004.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Sedor SF and Shao S: Mechanism of ASF1
engagement by CDAN1. Nat Commun. 16(2599)2025.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Gandhi S and Vasudevan D: Characterisation
of Entamoeba histolytica anti-silencing function 1 as a histone
chaperone. Biochimie. 241:72–85. 2026.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Zhang W, Tyl M, Ward R, Sobott F, Maman J,
Murthy AS, Watson AA, Fedorov O, Bowman A, Owen-Hughes T, et al:
Structural plasticity of histones H3-H4 facilitates their
allosteric exchange between RbAp48 and ASF1. Nat Struct Mol Biol.
20:29–35. 2013.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Srivastava DK, Gunjan S, Das C, Seshadri V
and Roy S: Structural insights into histone chaperone Asf1 and its
characterization from Plasmodium falciparum. Biochem J.
478:1117–1136. 2021.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Sunavala-Dossabhoy G: Preserving salivary
gland physiology against genotoxic damage-the Tousled way. Oral
Dis. 24:1390–1398. 2018.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Apta-Smith MJ, Hernandez-Fernaud JR and
Bowman AJ: Evidence for the nuclear import of histones H3.1 and H4
as monomers. EMBO J. 37(e98714)2018.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Groth A, Corpet A, Cook AJ, Roche D,
Bartek J, Lukas J and Almouzni G: Regulation of replication fork
progression through histone supply and demand. Science.
318:1928–1931. 2007.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Breuer J, Ferreira DEA, Kramer M,
Bollermann J and Nowrousian M: Functional analysis of
chromatin-associated proteins in Sordaria macrospora reveals
similar roles for RTT109 and ASF1 in development and DNA damage
response. G3 (Bethesda). 14(jkae019)2024.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Zhong Z, Wang Y, Wang M, Yang F, Thomas
QA, Xue Y, Zhang Y, Liu W, Jami-Alahmadi Y, Xu L, et al: Histone
chaperone ASF1 mediates H3.3-H4 deposition in Arabidopsis. Nat
Commun. 13(6970)2022.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Horard B, Sapey-Triomphe L, Bonnefoy E and
Loppin B: ASF1 is required to load histones on the HIRA complex in
preparation of paternal chromatin assembly at fertilization.
Epigenetics Chromatin. 11(19)2018.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Gao Y, Gan H, Lou Z and Zhang Z: Asf1a
resolves bivalent chromatin domains for the induction of
lineage-specific genes during mouse embryonic stem cell
differentiation. Proc Natl Acad Sci USA. 115:E6162–E6171.
2018.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Turner EL, Malo ME, Pisclevich MG, Dash
MD, Davies GF, Arnason TG and Harkness TA: The Saccharomyces
cerevisiae anaphase-promoting complex interacts with multiple
histone-modifying enzymes to regulate cell cycle progression.
Eukaryot Cell. 9:1418–1431. 2010.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Yang S, Liu L, Cao C, Song N, Wang Y, Ma
S, Zhang Q, Yu N, Ding X, Yang F, et al: USP52 acts as a
deubiquitinase and promotes histone chaperone ASF1A stabilization.
Nat Commun. 9(1285)2018.PubMed/NCBI View Article : Google Scholar
|
|
19
|
An T, Lu Y, Gong Z, Wang Y, Su C, Tang G
and Hou J: Research progress for targeting deubiquitinases in
gastric cancers. Cancers (Basel). 14(5831)2022.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Cote JM, Kuo YM, Henry RA, Scherman H,
Krzizike DD and Andrews AJ: Two factor authentication: Asf1
mediates crosstalk between H3 K14 and K56 acetylation. Nucleic
Acids Res. 47:7380–7391. 2019.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Zhu M, Zhang H, Lu F, Wang Z, Wu Y, Chen
H, Fan X, Yin Z and Liang F: USP52 inhibits cell proliferation by
stabilizing PTEN protein in non-small cell lung cancer. Biosci Rep.
41(BSR20210486)2021.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Huang TH, Shen ZJ, Sleckman BP and Tyler
JK: The histone chaperone ASF1 regulates the activation of ATM and
DNA-PKcs in response to DNA double-strand breaks. Cell Cycle.
17:1413–1424. 2018.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Segura-Bayona S, Knobel PA, González-Burón
H, Youssef SA, Peña-Blanco A, Coyaud É, López-Rovira T, Rein K,
Palenzuela L, Colombelli J, et al: Differential requirements for
Tousled-like kinases 1 and 2 in mammalian development. Cell Death
Differ. 24:1872–1885. 2017.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Lee KY, Im JS, Shibata E and Dutta A:
ASF1a promotes Non-homologous end joining repair by facilitating
phosphorylation of MDC1 by ATM at Double-Strand Breaks. Mol Cell.
68:61–75.e5. 2017.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Liu Z, Yang L, Sun Y, Xie X and Huang J:
ASF1a enhances antiviral immune response by associating with CBP to
mediate acetylation of H3K56 at the Ifnb promoter. Mol Immunol.
78:57–64. 2016.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Dong M, Zhang Y, Chen M, Tan Y, Min J, He
X, Liu F, Gu J, Jiang H, Zheng L, et al: ASF1A-dependent
P300-mediated histone H3 lysine 18 lactylation promotes
atherosclerosis by regulating EndMT. Acta Pharm Sin B.
14:3027–3048. 2024.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Simon B, Lou HJ, Huet-Calderwood C, Shi G,
Boggon TJ, Turk BE and Calderwood DA: Tousled-like kinase 2 targets
ASF1 histone chaperones through client mimicry. Nat Commun.
13(749)2022.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Wang X, Wang L, Dou J, Yu T, Cao P, Fan N,
Borjigin U and Nashun B: Distinct role of histone chaperone Asf1a
and Asf1b during fertilization and pre-implantation embryonic
development in mice. Epigenetics Chromatin. 14(55)2021.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Lin HY, Mohammadhosseini M, McClatchy J,
Villamor-Payà M, Jeng S, Bottomly D, Tsai CF, Posso C, Jacobson J,
Adey A, et al: The TLK-ASF1 histone chaperone pathway plays a
critical role in IL-1β-mediated AML progression. Blood.
143:2749–2762. 2024.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Hu X, Zhu H, Zhang X, He X and Xu X:
Comprehensive analysis of pan-cancer reveals potential of ASF1B as
a prognostic and immunological biomarker. Cancer Med. 10:6897–6916.
2021.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Li R, Cui X, Sun W, Yang Z, Shen X and Zhu
C: ASF1B, as an independent prognostic biomarker, correlates with
immune infiltrates in hepatocellular carcinoma. Comb Chem High
Throughput Screen. 26:1311–1323. 2023.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Zhang W, Gao Z, Guan M, Liu N, Meng F and
Wang G: ASF1B promotes oncogenesis in lung adenocarcinoma and other
cancer types. Front Oncol. 11(731547)2021.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Ouyang X, Lv L, Zhao Y, Zhang F, Hu Q, Li
Z, Zhu D and Li L: ASF1B serves as a potential therapeutic target
by influencing cell cycle and proliferation in hepatocellular
carcinoma. Front Oncol. 11(801506)2022.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Zhao C, Zhou J, Xing J and Yin Q: ASF1B
acted as a prognostic biomarker for stomach adenocarcinoma.
Medicine (Baltimore). 102(e35408)2023.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Zhang S, Xu L, Feng J, Tan D, Zhu Y, Hou
J, Li W, Lv K, Wang W, Jiang L, et al: ASF1B is a promising
prognostic biomarker and correlates with immunotherapy efficacy in
hepatocellular carcinoma. Front Genet. 13(842351)2022.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Yin X, Zhou M, Zhang L, Fu Y, Xu M, Wang
X, Cui Z, Gao Z, Li M, Dong Y, et al: Histone chaperone ASF1A
accelerates chronic myeloid leukemia blast crisis by activating
Notch signaling. Cell Death Dis. 13(842)2022.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Kang K, Nie H, Kuang W, Li X and Zhou Y: A
novel telomere-associated genes signature for the prediction of
prognosis and treatment responsiveness of hepatocellular carcinoma.
Biol Proced Online. 27(8)2025.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Huang W, Lin T, Huang L, Wu J, Hong J, Qiu
F, Tian Y and Wang Y: miR-24-3p Regulates Epithelial-mesenchymal
transition and the malignant phenotype of pancreatic adenocarcinoma
by regulating ASF1B expression. Biochem Genet. 61:742–761.
2023.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Kim JH, Youn Y, Lee JC, Kim J, Ryu JK and
Hwang JH: Downregulation of ASF1B inhibits tumor progression and
enhances efficacy of cisplatin in pancreatic cancer. Cancer
Biomark. 34:647–659. 2022.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Zhang Z and Liu S: The interaction between
ASF1B and TLK1 promotes the malignant progression of low-grade
glioma. Ann Med. 55:1111–1122. 2023.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Yu GH, Gong XF, Peng YY and Qian J:
Anti-silencing function 1B knockdown suppresses the malignant
phenotype of colorectal cancer by inactivating the
phosphatidylinositol 3-kinase/AKT pathway. World J Gastrointest
Oncol. 14:2353–2366. 2022.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Zhang M, Zhang L, Zhou M, Wang E, Meng B
and Li Q, Wang X, Wang Y and Li Q: Anti-silencing function 1B
promotes the progression of pancreatic cancer by activating c-Myc.
Int J Oncol. 62(8)2023.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Qiu W, Wu X, Shi H, Liu B, Li L, Wu W and
Lin J: ASF1B: A possible prognostic marker, therapeutic target, and
predictor of immunotherapy in male thyroid carcinoma. Front Oncol.
12(678025)2022.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Zhao Z, Cai Z, Zhang S, Yin X, Jiang T,
Shen C, Yin Y, Sun H, Chen Z, Han J and Zhang B: Activation of the
FOXM1/ASF1B/PRDX3 axis confers hyperproliferative and antioxidative
stress reactivity to gastric cancer. Cancer Lett.
589(216796)2024.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Li F, Wang H, Ye T, Guo P, Lin X, Hu Y,
Wei W, Wang S and Ma G: Recent advances in material technology for
leukemia treatments Adv. Mater. 36(e2313955)2024.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Goel H, Kumar R, Tanwar P, Upadhyay TK,
Khan F, Pandey P, Kang S, Moon M, Choi J, Choi M, et al: Unraveling
the therapeutic potential of natural products in the prevention and
treatment of leukemia. Biomed Pharmacother.
160(114351)2023.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Döhner H, Estey E, Grimwade D, Amadori S,
Appelbaum FR, Büchner T, Dombret H, Ebert BL, Fenaux P, Larson RA,
et al: Diagnosis and management of AML in adults: 2017 ELN
recommendations from an international expert panel. Blood.
129:424–447. 2017.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Azizidoost S, Nasrolahi A,
Sheykhi-Sabzehpoush M, Anbiyaiee A, Khoshnam SE, Farzaneh M and
Uddin S: Signaling pathways governing the behaviors of leukemia
stem cells. Genes Dis. 11:830–846. 2023.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Sicurella M, De Chiara M and Neri LM:
Hedgehog and PI3K/Akt/mTOR signaling pathways involvement in
leukemic malignancies: Crosstalk and role in cell death. Cells.
14(269)2025.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Jiang RY, Zhu JY, Zhang HP, Yu Y, Dong ZX,
Zhou HH and Wang X: STAT3: Key targets of growth-promoting receptor
positive breast cancer. Cancer Cell Int. 24(356)2024.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249.
2021.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Stavast CJ, van Zuijen I and Erkeland SJ:
MicroRNA-139, an Emerging Gate-Keeper in Various Types of Cancer.
Cells. 11(769)2022.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Feng S, Ma S, Li K, Gao S, Ning S, Shang
J, Guo R, Chen Y, Blumenfeld B, Simon I, et al: RIF1-ASF1-mediated
high-order chromatin structure safeguards genome integrity. Nat
Commun. 13(957)2022.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Machelová A, Dadejová MN, Franek M,
Mougeot G, Simon L, Le Goff S, Duc C, Bassler J, Demko M,
Schwarzerová J, et al: The histone chaperones ASF1 and HIRA are
required for telomere length and 45S rDNA copy number homeostasis.
Plant J. 120:1125–1141. 2024.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Tang M, Chen Z, Wang C, Feng X, Lee N,
Huang M, Zhang H, Li S, Xiong Y and Chen J: Histone chaperone ASF1
acts with RIF1 to promote DNA end joining in BRCA1-deficient cells.
J Biol Chem. 298(101979)2022.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Kim MA, Kim B, Jeon J, Lee J, Jang H, Baek
M, Seo SU, Shin D, Dutta A and Lee KY: Tousled-like kinase loss
confers PARP inhibitor resistance in BRCA1-mutated cancers by
impeding non-homologous end joining repair. Mol Med.
31(18)2025.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Lee SB, Chang TY, Lee NZ, Yu ZY, Liu CY
and Lee HY: Design, synthesis and biological evaluation of
bisindole derivatives as anticancer agents against Tousled-like
kinases. Eur J Med Chem. 227(113904)2022.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Al Kamzari KAM and Constantinou C:
Navigating the colorectal cancer maze: Unveiling pathways to
diagnosis, management, pathophysiology and prevention. Curr Oncol
Rep. 27:1115–1130. 2025.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Zhang X, Hou H, Jiang M and Zhang X:
Aberrant circulating tumor DNA methylation and exosomal microRNA
biomarkers for early detection of colorectal cancer. Mol Biol Rep.
50:2743–2750. 2023.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Kelson CO and Zaytseva YY: Altered lipid
metabolism in APC-driven colorectal cancer: The potential for
therapeutic intervention. Front Oncol. 14(1343061)2024.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Chen Q, Xu L, Wu T, Li J and Hua L:
Analysis of abnormal intestinal flora on risk of intestinal cancer
and effect of heparin on formation of bacterial biofilm.
Bioengineered. 13:894–904. 2022.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Li J, Ma X, Chakravarti D, Shalapour S and
DePinho RA: Genetic and biological hallmarks of colorectal cancer.
Genes Dev. 35:787–820. 2021.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Corpet A and Almouzni G: Making copies of
chromatin: The challenge of nucleosomal organization and epigenetic
information. Trends Cell Biol. 19:29–41. 2009.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Liang X, Yuan X, Yu J, Wu Y, Li K, Sun C,
Li S, Shen L, Kong F, Jia J, et al: Histone chaperone ASF1A
predicts poor outcomes for patients with gastrointestinal cancer
and drives cancer progression by stimulating transcription of
β-Catenin target genes. EBioMedicine. 21:104–116. 2017.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Qiu F, Wang Y, Chu X and Wang J: ASF1A
regulates H4Y72 phosphorylation and promotes autophagy in colon
cancer cells via a kinase activity. Artif Cells Nanomed Biotechnol.
47:2754–2763. 2019.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Fan Z, Zhou P, Jin B, Li G, Feng L, Zhuang
C and Wang S: Recent therapeutics in hepatocellular carcinoma. Am J
Cancer Res. 13:261–275. 2023.PubMed/NCBI
|
|
67
|
Nadarevic T, Giljaca V, Colli A, Fraquelli
M, Casazza G, Miletic D and Štimac D: Computed tomography for the
diagnosis of hepatocellular carcinoma in adults with chronic liver
disease. Cochrane Database Syst Rev. 10(CD013362)2021.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Nadarevic T, Colli A, Giljaca V, Fraquelli
M, Casazza G, Manzotti C, Štimac D and Miletic D: Magnetic
resonance imaging for the diagnosis of hepatocellular carcinoma in
adults with chronic liver disease. Cochrane Database Syst Rev.
5(CD014798)2022.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Sharma KK, Mohsin M, Mittal P, Ali Z,
Fatma N, Upadhyay P, Gupta R, Verma A and Kumar G: Diagnosis of the
initial stage of hepatocellular carcinoma: A review. Curr Pharm
Des. 30:1708–1724. 2024.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Karaoğullarından Ü, Üsküdar O, Odabaş E,
Ak N and Kuran S: Hepatocellular carcinoma in cirrhotic versus
noncirrhotic livers: Clinicomorphologic findings and prognostic
factors. Turk J Gastroenterol. 34:262–269. 2023.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Nong W, Ma L, Lan B, Liu N, Yang H, Lao X,
Deng Q and Huang Z: Comprehensive identification of bridge genes to
explain the progression from chronic hepatitis B virus infection to
hepatocellular carcinoma. J Inflamm Res. 14:1613–1624.
2021.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Kitab B and Tsukiyama-Kohara K: Regulatory
role of ribonucleotide reductase subunit M2 in hepatocyte growth
and pathogenesis of hepatitis C Virus. Int J Mol Sci.
24(2619)2023.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Di Ciaula A, Bonfrate L, Krawczyk M,
Frühbeck G and Portincasa P: Synergistic and detrimental effects of
alcohol intake on progression of liver steatosis. Int J Mol Sci.
23(2636)2022.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Thomas JA, Kendall BJ, El-Serag HB, Thrift
AP and Macdonald GA: Hepatocellular and extrahepatic cancer risk in
people with non-alcoholic fatty liver disease. Lancet Gastroenterol
Hepatol. 9:159–169. 2024.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Tsuzaki J, Ueno A, Masugi Y, Tamura M,
Yamazaki S, Matsuda K, Kurebayashi Y, Sakai H, Yokoyama Y, Abe Y,
et al: Chronological changes in etiology, pathological and imaging
findings in primary liver cancer from 2001 to 2020. Jpn J Clin
Oncol. 55:362–371. 2025.PubMed/NCBI View Article : Google Scholar
|
|
76
|
Wu Y, Li X, Yu J, Björkholm M and Xu D:
ASF1a inhibition induces p53-dependent growth arrest and senescence
of cancer cells. Cell Death Dis. 10(76)2019.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Xia JY and Aadam AA: Advances in screening
and detection of gastric cancer. J Surg Oncol. 125:1104–1109.
2022.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Wang D, An TY, Hu QM, Hua YQ, Ni P, Jia B,
Duan GC and Chen SY: Helicobacter pylori promotes
YTHDF2-mediated SRA1 m6A modification and promotes the occurrence
and development of gastric cancer. Eur J Gastroenterol Hepatol.
37:717–727. 2025.PubMed/NCBI View Article : Google Scholar
|
|
79
|
Shan W, Li G, Zhang H, Zhang R and Liu J,
Gao L, Li Y, Fan L, Yang C and Liu J: TAP1 promotes immune escape
by activating JNK/STAT1/PD-L1 signaling in EBV-associated gastric
cancer. Mol Cell Biochem. 480:5429–5446. 2025.PubMed/NCBI View Article : Google Scholar
|
|
80
|
Bounder G, Jouimyi MR, Essaidi I, Elyounsi
I, Boura H, Michel V, Badre W, Touati E and Maachi F: Upstream
stimulating factor 1 (USF1)-202 G/A polymorphism and serum levels
of USF1 and USF2 are associated with gastric cancer risk: A case
control study. J Cancer Res Clin Oncol. 151(113)2025.PubMed/NCBI View Article : Google Scholar
|
|
81
|
Xiu J, Ma L, Ding Y, Li Y, Kan L, Feng S,
Lu X, He T and Han Z: The diagnosis of early gastric cancer based
on medical imaging technology and mathematical modeling. Comput
Math Methods Med. 2022(8721654)2022.PubMed/NCBI View Article : Google Scholar
|
|
82
|
Negishi R, Yamakawa H, Kobayashi T,
Horikawa M, Shimoyama T, Koizumi F, Sawada T, Oboki K, Omuro Y,
Funasaka C, et al: Transcriptomic profiling of single circulating
tumor cells provides insight into human metastatic gastric cancer.
Commun Biol. 5(20)2022.PubMed/NCBI View Article : Google Scholar
|
|
83
|
Li H, Zhao J, Sun J, Tian C, Jiang Q, Ding
C, Gan Q, Shu P, Wang X, Qin J and Sun Y: Demethylation of the
SFRP4 promoter drives gastric cancer progression via the Wnt
pathway. Mol Cancer Res. 19:1454–1464. 2021.PubMed/NCBI View Article : Google Scholar
|
|
84
|
Cheng Q, Li X, Shen L and Yang T: Network
pharmacology analysis and experimental verification of weinaian
capsule for treating gastric cancer. Curr Pharm Biotechnol.
27:95–107. 2026.PubMed/NCBI View Article : Google Scholar
|
|
85
|
Zhang P, Liu D, Zang Y, Wang J, Liu Z, Zhu
J, Li X and Ding Y: USP12 facilitates gastric cancer progression
via stabilizing YAP. Cell Death Discov. 10(174)2024.PubMed/NCBI View Article : Google Scholar
|
|
86
|
Chen C, Bao H, Lin W, Chen X, Huang Y,
Wang H, Yang Y, Liu J, Lv X and Teng L: ASF1b is a novel prognostic
predictor associated with cell cycle signaling pathway in gastric
cancer. J Cancer. 13:1985–2000. 2022.PubMed/NCBI View Article : Google Scholar
|
|
87
|
Shi X, Liu T, Pei P, Shen W, Hu L, Zhu R,
Wang F, Chen C and Yang K: Radionuclide-Labeled antisilencing
function 1a inhibitory peptides for tumor identification and
individualized therapy. ACS Nano. 18:9114–9127. 2024.PubMed/NCBI View Article : Google Scholar
|
|
88
|
Liao LZ, Wu CJ, Chen YA, Lin TC, Lin PH,
Wei CL and Wu KJ: Histone 3 lysine 56 acetylation (H3K56ac)
regulates extrachromosomal DNA (ecDNA) hub maintenance. Neoplasia.
72(101269)2026.PubMed/NCBI View Article : Google Scholar
|
|
89
|
Vogt A, Szurgot M, Gardner L, Schultz DC
and Marmorstein R: HIRA complex deposition of histone H3.3 is
driven by histone tetramerization and histone-DNA binding. J Biol
Chem. 300(107604)2024.PubMed/NCBI View Article : Google Scholar
|
|
90
|
Tavakoli Z, Khajeh K and Ranjbar B: A
hybrid nanosystem for prostate cancer therapy: Codelivery of
enzalutamide and curcumin via Selenium-Embedded mesoporous silica
and chitosan nanoparticles. ChemistryOpen.
15(e202500589)2026.PubMed/NCBI View Article : Google Scholar
|
|
91
|
Sekhoacha M, Riet K, Motloung P, Gumenku
L, Adegoke A and Mashele S: Prostate cancer review: Genetics,
diagnosis, treatment options, and alternative approaches.
Molecules. 27(5730)2022.PubMed/NCBI View Article : Google Scholar
|
|
92
|
Godtman RA, Kollberg KS, Pihl CG, Månsson
M and Hugosson J: The association between age, prostate cancer
risk, and higher Gleason score in a Long-term screening program:
Results from the Göteborg-1 prostate cancer screening trial. Eur
Urol. 82:311–317. 2022.PubMed/NCBI View Article : Google Scholar
|
|
93
|
Chen J, Zhang D, Yan W, Yang D and Shen B:
Translational bioinformatics for diagnostic and prognostic
prediction of prostate cancer in the next-generation sequencing
era. Biomed Res Int. 2013(901578)2013.PubMed/NCBI View Article : Google Scholar
|
|
94
|
Mytych W, Bartusik-Aebisher D, Łoś A,
Dynarowicz K, Myśliwiec A and Aebisher D: Photodynamic therapy for
atherosclerosis. Int J Mol Sci. 25(1958)2024.PubMed/NCBI View Article : Google Scholar
|
|
95
|
Teng R, Gao L, Sun X, Zhang E, Sun Y and
Li S: Effects of Glycine on epigenetic modification and early
embryonic development in porcine oocytes exposed to monobutyl
phthalate. Reprod Toxicol. 129(108684)2024.PubMed/NCBI View Article : Google Scholar
|
|
96
|
Meng L, Hu H, Liu Z, Zhang L, Zhuan Q, Li
X, Fu X, Zhu S and Hou Y: The Role of Ca²+ in maturation
and reprogramming of bovine Oocytes: A system study of Low-calcium
model. Front Cell Dev Biol. 9(746237)2021.PubMed/NCBI View Article : Google Scholar
|
|
97
|
Liu K, Yin C, Ye W, Ma M, Wang Y, Wang P
and Fang Y: Histone variant H3.3 controls arabidopsis fertility by
regulating male gamete development. Plant Cell Physiol. 65:68–78.
2024.PubMed/NCBI View Article : Google Scholar
|
|
98
|
Hu S, Liu Y, Yang Y and Xu L: Structural
insights into instability of the nucleosome driven by histone
variant H3T. Biochem Biophys Res Commun. 727(150307)2024.PubMed/NCBI View Article : Google Scholar
|
|
99
|
Bakail M, Gaubert A, Andreani J, Moal G,
Pinna G, Boyarchuk E, Gaillard MC, Courbeyrette R, Mann C, Thuret
JY, et al: Design on a rational basis of High-Affinity peptides
inhibiting the histone chaperone ASF1. Cell Chem Biol.
26:1573–1585.e10. 2019.PubMed/NCBI View Article : Google Scholar
|
|
100
|
GTEx Consortium: The GTEx Consortium atlas
of genetic regulatory effects across human tissues. Science.
369:1318–1330. 2020.PubMed/NCBI View Article : Google Scholar
|
|
101
|
Liu Y, Liu S, Jing R, Li C, Guo Y, Cai Z,
Xi P, Dai P, Jia L, Zhu H and Zhang X: Identification of ASF1A and
HJURP by global H3-H4 histone chaperone analysis as a prognostic
two-gene model in hepatocellular carcinoma. Sci Rep.
14(7666)2024.PubMed/NCBI View Article : Google Scholar
|
|
102
|
Bukkuri A and Adler FR: Biomarkers or
biotargets? Using competition to lure cancer cells into
evolutionary traps. Evol Med Public Health. 11:264–276.
2023.PubMed/NCBI View Article : Google Scholar
|
|
103
|
Deng K, Feng W, Liu X, Su X, Zuo E, Du S,
Huang Y, Shi D and Lu F: Anti-silencing factor 1A is associated
with genome stability maintenance of mouse preimplantation
embryos†. Biol Reprod. 102:817–827. 2020.PubMed/NCBI View Article : Google Scholar
|
